Efficacy—pembrolizumab plus chemotherapy versus chemotherapy
CPS
In the PD-L1 CPS ≥1 population, median OS was 16.5 months (95% CI, 12.8–19.6) with pembrolizumab plus chemotherapy versus 13.8 months (95% CI, 10.5–16.9) with chemotherapy (HR, 0.78; 95% CI, 0.53–1.16) (In the PD-L1 CPS ≥1 population, median PFS was 8.5 months (95% CI, 7.0–10.3) with pembrolizumab plus chemotherapy versus 6.5 months (95% CI, 4.2–7.1) with chemotherapy (HR, 0.64; 95% CI, 0.44–0.94) (